---
title: Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths
nct_id: NCT00107042
overall_status: COMPLETED
phase: PHASE2
sponsor: University of North Carolina, Chapel Hill
study_type: INTERVENTIONAL
primary_condition: Hepatitis B
countries: United States, Puerto Rico
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00107042.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00107042"
ct_last_update_post_date: 2017-03-29
last_seen_at: "2026-05-12T07:04:04.396Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths

**Official Title:** Hepatitis B Vaccination in Youth at Adolescent Trial Network Sites: Effectiveness of Two Strategies and Evaluation of Tools To be Used in Future HIV Prevention Trials.

**NCT ID:** [NCT00107042](https://clinicaltrials.gov/study/NCT00107042)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 123
- **Lead Sponsor:** University of North Carolina, Chapel Hill
- **Collaborators:** Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- **Conditions:** Hepatitis B
- **Start Date:** 2004-02
- **Completion Date:** 2008-07
- **CT.gov Last Update:** 2017-03-29

## Brief Summary

This study will evaluate 2 licensed vaccine products (Recombivax and Twinrix) given in a two-dose schedule to youth at risk for hepatitis B and HIV infection to evaluate immunogenicity of the products in this population, barriers to vaccine delivery, and factors which predict a diminished immune response. Since these youths are also potential candidates for future HIV vaccine trials, this study will also include preliminary assessment of youths' understanding of informed consent forms, and willingness to participate in a vaccine trial and return for multiple visits (including blood draws for immunologic assessment).

## Detailed Description

Hepatitis B (HBV) prophylactic immunization has been recommended for at-risk adolescents for more than 10 years although universal coverage has not been achieved. Vaccine response in healthy adolescents has generally been reported to be excellent. But, data from the study Reaching for Excellence in Adolescent Care and Health (REACH) that studied HIV-negative adolescents who were at-risk of acquiring Hepatitis B infection through sexual or needle sharing behaviors has demonstrated a much lower than expected vaccine response rate in this population using standard vaccine dosing. Some data suggest that factors such as gender or body mass index might be responsible for the differences in response to the vaccine observed in individuals. The reason for the diminished vaccine response in this population is unclear. If in fact, Hepatitis B vaccine response is diminished in this population, then efforts to determine correlates of response and to improve the response are warranted. The proposed trial will evaluate 2 licensed vaccine products given in a two-dose schedule in youth at risk for hepatitis B and HIV infection to evaluate immunogenicity of the products in this population, barriers to vaccine delivery, and factors which predict a diminished immune response.

Since these youths are also potential candidates for future HIV vaccine trials, participation in such trials will require ability to understand and willingness to volunteer for such trials, ability to return for multiple vaccinations and blood draws to assess vaccine response, and willingness to participate in HIV prevention education. A hepatitis B vaccine trial will provide a licensed vaccine to youth in whom the vaccine is indicated and will allow preliminary assessment of youth's willingness to participate in a vaccine trial that involves blood draws for immunologic assessment.

Tools that will be necessary for HIV vaccine trials in youth include a youth-friendly simplified vaccine trial education component with a required written test for the participant, a standardized risk reduction education program, and a computer-assisted assessment of youth behaviors. These tools can be finalized and field tested in youth participating in the hepatitis B vaccine trial without promoting a false sense of protection from HIV. Secondary objectives of this trial will include assessment of a number of ancillary tools crucial for future HIV vaccine trials. This Hepatitis B vaccine trial will also serve as a HIV vaccine preparedness trial for youth at risk for both Hepatitis B and HIV.

Design: This is a phase II, randomized, single-blinded trial of two hepatitis B immunization regimens in 150 HIV-negative, hepatitis B core antibody, hepatitis B surface antigen and surface antibody negative youth. Vaccinations will be given in a two-dose regimen at 0 and six months (75 subjects in each arm) and the primary outcome will be seroresponsiveness one month after the 6-month dose. Safety and tolerability will also be assessed.

## Eligibility

- **Minimum age:** 12 Years
- **Maximum age:** 17 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* HIV negative youth age 12-17 years (No serologic evidence of HIV infection).
* Negative hepatitis B serology. (No serologic evidence of hepatitis B surface antigen (HBSAg), hepatitis B surface antibody (HBsAb or anti-HBs) and hepatitis B core antibody (HBcAb or anti-HBc)).
* Either no prior hepatitis B immunizations or unknown or incomplete hepatitis B immunization status.
* Willing to participate in HIV risk-reduction counseling and computer assisted measurement of behaviors.
* Parent or legal guardian willing to provide written permission
* Females of childbearing potential must have a negative pregnancy test at screening and should agree to avoid pregnancy through the end of the vaccine phase of the study. Females who are engaging in sexual intercourse must be willing to practice a reliable method of birth control through the end of the vaccine-phase of the study (approximately 6 months). The decision of what is "reliable" is at the discretion of the site investigator.

Exclusion Criteria:

* Presence of any serious illness requiring treatment with systemic medications, excluding treatment for asthma.
* Previous allergic reaction to any vaccines or to constituents of these vaccines (yeast, thimerosal or aluminum)
* Pregnancy
* Current immunomodulator therapy
* Receipt of immunosuppressor therapy (more than 10 mg/day of prednisone or equivalent for \>1 week) in the 6 months preceding entry or anticipated long-term corticosteroid therapy in the above dose and duration. Short term (\< 7 days) steroid use for the treatment of asthma is not an exclusion.
* Receipt of any vaccine within 2 weeks preceding study entry.
```

## Arms

- **1** (ACTIVE_COMPARATOR) — Participants receive doses of Recombivax at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
- **2** (EXPERIMENTAL) — Participants receive doses of Twinrix at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.

## Interventions

- **Recombivax** (BIOLOGICAL) — Participants receive doses of Recombivax at weeks 0 and 24.
- **Twinrix** (BIOLOGICAL) — Participants receive doses of Twinrix at weeks 0 and 24.

## Primary Outcomes

- **Qualitative Seroresponsiveness to Hepatitis B Surface Antigen** _(time frame: Week (Wk) 28 (One month after the second immunization))_ — Seroresponsiveness to Hepatitis B Surface Antigen is defined as follows:

Responder: serum antibody level is greater than or equal to 10 mIU/mL. Non-responder: serum antibody level is less than 10 mIU/mL.
- **Safety and Tolerability of Vaccine Regimens of Recombivax and Twinrix (Number of Participants With >=1 Adverse Event (AE))** _(time frame: Week 12, Week 24, Week 28, Week 76)_ — Frequency Distribution of AEs by Study Arm and Preferred Term. The safety and tolerability of each vaccine was assessed by measuring reactogenicity. The reactions were coded as "Any" vs. "None". In summarizing the distribution of AEs, the number of subjects with at least one event by preferred term and study arm were reported.
- **Safety and Tolerability of Vaccine Regimens of Recombivax and Twinrix: Serious Adverse Events (SAE)(Number of Subjects With >= 1 SAE)** _(time frame: Week 12, Week 24, Week 28, Week 76)_ — Frequency Distribution of SAE by Study Arm and Preferred Term. The safety and tolerability of each vaccine was assessed by measuring reactogenicity. The reactions were coded as "Any" vs. "None". The number of participants with at least one SAE is reported.

## Secondary Outcomes

- **Quantitative Vaccine Response** _(time frame: Week 28)_
- **Unadjusted Relationship of Hepatitis B Vaccine Response (Log10 Titer) and Potential Impact Factors Among Subjects Whose Week 28 Antibody Results Are Within Week 28 Visit Window.** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B (Hep B) Surface Antigen (Binary); Predictor: STUDY ARM.** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: SITE EFFECT** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: AGE** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: GENDER** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: HISPANIC ETHNICITY** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: RACE** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TANNER STAGE FOR FEMALES** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TANNER STAGE FOR MALES** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: BMI at Baseline** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER SMOKED CIGARETTES** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: SEXUAL IDENTITY** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: AGE AT WHICH SUBJECT FIRST HAD SEX (NOT FORCED)** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TOTAL LIFETIME SEX PARTNERS** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TOTAL LIFETIME MALE SEX PARTNERS** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TOTAL LIFETIME FEMALE SEX PARTNERS** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER DRANK ALCOHOL** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER SMOKED MARIJUANA** _(time frame: Week 28)_
- **Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER USED DRUGS NOT PRESCRIBE** _(time frame: Week 28)_
- **Immunogenicity to Hep B 18 Months After First Immunization** _(time frame: Week 76)_
- **Immunogenicity to Hep A in the Twinrix Arm: One Month Post 2nd Vaccination** _(time frame: Week 28)_
- **Immunogenicity to Hep A in Twinrix Arm: Twelve Months Post 2nd Vaccination** _(time frame: Week 76)_
- **Immunogenicity to Hep A in Twinrix Arm: Overall Response (1-month or 12-month After 2nd Vaccination)** _(time frame: Week 28 and Week 76)_
- **As Treated Analysis - Adequate Antibody Response to Hep B Surface Antigen** _(time frame: Week 28)_
- **Assessment of Youth Understanding of Vaccine Trial and Informed Consent** _(time frame: Screening)_

## Locations (11)

- Children's Hospital of Los Angeles, Los Angeles, California, United States
- University of California at San Diego, San Diego, California, United States
- University of California at San Francisco, San Francisco, California, United States
- Children's Hospital National Medical Center, Washington D.C., District of Columbia, United States
- University of Southern Florida College of Medicine, Tampa, Florida, United States
- Ruth M Rothstein CORE Center/ John H Stroger Jr Hospital, Chicago, Illinois, United States
- Tulane Medical Center, New Orleans, Louisiana, United States
- University of Maryland, Baltimore, Maryland, United States
- Montefiore Medical Center, The Bronx, New York, United States
- St. Jude Childrens Research Hospital, Memphis, Tennessee, United States
- Unversity of Peurto Rico School of Medicine, San Juan, Puerto Rico

## Recent Field Changes (last 30 days)

- `eligibility.sex` — added _(2026-05-12)_
- `locations.montefiore medical center|the bronx|new york|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.children's hospital of los angeles|los angeles|california|united states` — added _(2026-05-12)_
- `locations.university of california at san diego|san diego|california|united states` — added _(2026-05-12)_
- `locations.university of california at san francisco|san francisco|california|united states` — added _(2026-05-12)_
- `locations.children's hospital national medical center|washington d.c.|district of columbia|united states` — added _(2026-05-12)_
- `locations.university of southern florida college of medicine|tampa|florida|united states` — added _(2026-05-12)_
- `locations.ruth m rothstein core center/ john h stroger jr hospital|chicago|illinois|united states` — added _(2026-05-12)_
- `locations.tulane medical center|new orleans|louisiana|united states` — added _(2026-05-12)_
- `locations.university of maryland|baltimore|maryland|united states` — added _(2026-05-12)_
- `locations.st. jude childrens research hospital|memphis|tennessee|united states` — added _(2026-05-12)_
- `locations.unversity of peurto rico school of medicine|san juan||puerto rico` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00107042.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00107042*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*